Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
V540C is a quadrivalent vaccine developed by Merck Sharp & Dohme (MSD) for the prevention of infections and associated diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18. Marketed under the brand name Gardasil, it is composed of highly purified virus-like particles (VLPs) of the major capsid (L1) protein of each of the four HPV types. These VLPs are produced using recombinant DNA technology in *Saccharomyces cerevisiae* and are adsorbed onto an aluminum-containing adjuvant. The vaccine works by inducing a robust humoral immune response, generating neutralizing antibodies that prevent the virus from infecting host cells. It is indicated for the prevention of cervical, vulvar, vaginal, and anal cancers, as well as genital warts (condyloma acuminata) and various precancerous or dysplastic lesions associated with the targeted HPV types.
- Brand names
- GardasilSilgard
- Other names
- human papillomavirus quadrivalent vaccinequadrivalent human papillomavirus vaccineHPV 6/11/16/18 vaccine
02
Targets
HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV11 L1HPV16 (Human papillomavirus type 16)
Beyond the preview
Go deeper on human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant.